The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway. In August 2015, the European Commission authorized panobinostat for use in combination with bortezomib and dexamethasone for the treatment of relapsed or relapsed and refractory multiple myeloma (MM) in patients who have received ≥2 prior regimens including bortezomib and an immunomodulatory drug. In January 2016, the National Institute for Health and Care Excellence recommended panobinostat for use in the same combination and patient population. The authorization and recommendation were based on results from the pivotal phase 3 PANORAMA 1 (NCT01023308) clinical trial, which demonstrated an improvement in median progression-free survival of 7.8 months for the three-drug combination compared with placebo plus bortezomib and dexamethasone in this patient population. This review will discuss the current treatment landscape for relapsed/refractory MM, the mechanism of action of panobinostat, clinical data supporting the European authorization, concerns about safety and strategies for mitigating toxicity, and how panobinostat fits into the current MM landscape in Europe.



Editorial support, funded by Novartis Pharmaceuticals.
Clínica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain. sanmiguel@unav.es.
Jesus F
JF
San-Miguel
Medizinische Klinik und Poliklinik II, University of Würzburg, Würzburg, Germany.
Hermann
H
Einsele
University Hospital of Nantes, Nantes, France.
Philippe
P
Moreau
D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D000069286:Bortezomib / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology / Q000517:prevention & control*; D005060:Europe; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000503:physiopathology; D000077767:Panobinostat; D012008:Recurrence
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D000069286:Bortezomib; D003907:Dexamethasone; D000077767:Panobinostat
Multiple myeloma; Oncology; Panobinostat; Relapsed; Relapsed and refractory
Blood. 2008 Mar 1;111(5):2516-20
17975015
Mayo Clin Proc. 2004 Jul;79(7):867-74
15244382
Cancer Immunol Immunother. 2013 Dec;62(12):1841-9
24162108
Lancet Oncol. 2014 Oct;15(11):1195-206
25242045
PLoS One. 2010 Jul 09;5(7):e11483
20634887
Nat Rev Cancer. 2004 May;4(5):349-60
15122206
Leukemia. 2012 Jan;26(1):149-57
21799510
Blood. 2016 Jun 9;127(23):2833-40
27091875
J Immunol. 2011 Feb 1;186(3):1840-8
21187443
Clin Cancer Res. 2011 Dec 1;17(23):7313-23
21903769
Blood. 2013 Oct 3;122(14):2331-7
23950178
Cancers (Basel). 2013 Apr 15;5(2):430-61
24216985
J Clin Oncol. 2012 Jul 10;30(20):2475-82
22585692
Leukemia. 2009 Nov;23(11):2147-52
19626046
Blood. 2011 Jan 13;117(2):553-62
20944071
N Engl J Med. 2007 Nov 22;357(21):2123-32
18032762
N Engl J Med. 2007 Nov 22;357(21):2133-42
18032763
Cancer Res. 2007 Jul 1;67(13):6383-91
17616698
MAbs. 2015;7(2):311-21
25760767
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
Blood. 2014 Jul 3;124(1):84-95
24787006
Lancet Oncol. 2014 Nov;15(12):e538-48
25439696
Immunol Rev. 2016 Mar;270(1):95-112
26864107
Blood. 2012 Jul 19;120(3):552-9
22184404
Blood. 2006 Nov 15;108(10):3441-9
16728695
Blood. 2016 Jul 7;128(1):37-44
27216216
Cancer Res. 2002 Sep 1;62(17):4996-5000
12208752
Cell. 2003 Dec 12;115(6):727-38
14675537
Science. 2014 Jan 17;343(6168):301-5
24292625
Lancet. 2016 Apr 9;387(10027):1551-1560
26778538
Cancer Lett. 2009 Aug 8;280(2):233-41
19344997
Blood. 2016 Feb 11;127(6):713-21
26631116
Lancet Oncol. 2013 Oct;14(11):1129-1140
24055414
Clin Cancer Res. 2008 May 1;14(9):2775-84
18451245
Br J Haematol. 2013 Aug;162(4):559-62
23692150
Br J Cancer. 2013 Aug 6;109(3):676-85
23868005
Blood. 2006 Nov 15;108(10):3458-64
16840727
Bone Marrow Transplant. 2016 Apr;51(4):479-91
26726946
Lancet Oncol. 2016 Jan;17(1):27-38
26671818
Blood. 2011 Nov 3;118(18):4771-9
21860026
Blood. 2002 Nov 1;100(9):3063-7
12384400
Leukemia. 2014 Feb;28(2):258-68
23868105
Am J Clin Pathol. 2004 Apr;121(4):482-8
15080299
N Engl J Med. 2015 Sep 24;373(13):1207-19
26308596
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8
10468620
Blood. 2013 Feb 7;121(6):893-7
23393020
Epigenetics. 2014 Nov;9(11):1511-20
25482492
Blood. 2006 Jun 15;107(12):4907-16
16507771
Blood. 2013 Jul 11;122(2):219-26
23699600
Cancer Res. 2010 Mar 1;70(5):1970-80
20160034
Nat Rev Clin Oncol. 2015 Jan;12(1):42-54
25421279
Mol Cancer Ther. 2011 Nov;10(11):2034-42
22072815
Blood. 2010 Jul 22;116(3):406-17
20351311
Lancet Oncol. 2013 Oct;14(11):1055-1066
24007748
Eur J Cancer. 2013 Apr;49(6):1374-403
23485231
N Engl J Med. 2015 Aug 13;373(7):621-31
26035255
Blood. 2011 Mar 31;117(13):3658-68
21292776
Leukemia. 2016 Feb;30(2):399-408
26338273
N Engl J Med. 2011 Mar 17;364(11):1046-60
21410373
Br J Haematol. 2010 Mar;148(5):702-13
19912222
Blood. 2016 May 26;127(21):2561-8
26932802
Science. 2014 Jan 17;343(6168):305-9
24292623
Leukemia. 2011 Feb;25(2):362-5
21109772
Biologics. 2010 Sep 28;4:273-87
21116326
Haematologica. 2010 May;95(5):794-803
19951978
N Engl J Med. 2015 Jan 8;372(2):142-52
25482145